Newer therapies in osteoporosis

Indian Journal of Rheumatology

Volumn 3, Issue 4, 2008, Pages 148-157

  Kanakamani, J ^a   Tandon, Nikhil ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anabolic therapy; Antiresorptive therapy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALPHAVBETA6 INTEGRIN; BAZEDOXIFENE; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; DENOSUMAB; DKK 1 INHIBITOR; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LASOFOXIFENE; MACROFLUX; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DIVERTICULITIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; GENE ACTIVATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERURICEMIA; HYPOCALCEMIA; LABYRINTHITIS; LEG CRAMP; NAUSEA; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK REDUCTION; SCLERODERMA; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA FRACTURE; VIRUS PNEUMONIA;

EID: 84992229882     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60141-0     Document Type: Review

References (57)

1. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-9.
2. Malhotra N, Mithal A. Osteoporosis in Indians. Indian J Med Res 2008; 127: 263-8.
3. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endoer Rev 2002; 23: 570-8.
4. Cauley JA, Robbins J, Chen Z, et al., for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38.
5. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, et al. Non-compliance: the Achilles'heel of anti-fracture efficacy. Osteoporos Int 2007; 18: 711-9.
6. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Rep 2008; 10: 97-101.
7. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
9. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905-16.
10. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5.
11. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006; 7: 51-65.
12. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-34.
13. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989; 83: 60-5.
14. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.
15. Black DM, Delmas PD, Eastell R, Rein IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
16. Reginster JY, Adami S, Lakatos P, Greewald M, Stephan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-61.
17. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-8.
18. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46.
19. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35: 488-97.
20. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelson T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
21. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 2000; 141: 1338-44.
22. Miller PD, Christiansen C, Hoeck HC, et al. Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis: results of a 2-year, phase III, placebo- and active-controlled study. J Bone Miner Res 2007; 22(Suppl 1): S59.
23. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopoausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2007; 22(Suppl 1): S58.
24. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-66.
25. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-31.
26. Miller PD, Bolognese MA, Lewiecki EM, et al., for the Amg 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; Apr 26.
27. Stoch SA, Miller DL, Van Dyck K, et al. Effect of cathepsin K inhibition on bone resorption markers in healthy postmenopausal women. American Society for Bone and Mineral Research. Philadelphia, PA (2006).
28. Adamil S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. American Society for Bone and Mineral research. Philadelphia, PA (2006).
29. Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007; 40: 122-31.
30. Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437-49.
31. Hannon R, Eastell R, Clack G, et al. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. European Calcified Tissue Society Meeting. Geneva (2005).
32. 3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005; 90: 2022-8.
33. 3 blocking antibody, inhibits osteoclastic resorption by decreasing the number of attached osteoclasts. J Bone Miner Res 2004; 19(Suppl 1): S154.
34. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
35. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006; 21: 1785-90.
36. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14: 77-81.
37. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
38. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-39.
39. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res 2007; 22: 334.
40. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005; 353: 566-75.
41. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubibi D, Carozza M, et al. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001; 18: 964-70.
42. Gopalakrishnan V, Hwang S, Loughre H. Administration of hPTH to humans using Macroflux transdermal technology results in the rapid delivery of biologically active PTH. J Bone Miner Res 2004; 19(Suppl 1): S460.
43. Matsumoto T, Shiraki M, Nakamura T, Hagino H, Iinuma H, Nakamura T. Daily nasal spray of hPTH (1-34) for 3 months increases bone mass in osteoporotic subjects. Osteoporos Int 2006; 17: 1532-8.
44. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 569-75.
45. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105: 1595-604.
46. Grey A. Emerging pharmacologic therapies for osteoporosis. Expert Opin Emerg Drugs 2007; 12: 493-508.
47. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006; 4: CDO05326.
48. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Cmpston J, Phenekos C, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
49. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995; 10: 1844-52.
50. Conover CA, Johnstone EW, Turner RT, Evans GL, John Ballard FJ, Doran PM, et al. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res 2002; 12: 178-83.
51. Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, et al. Preptin, another peptide product of the pancreatic β-cell, cell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab 2007; 292: E117-E22.
52. Warmington K, Ominsky M, Bolon B, et al. Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J Bone Miner Res 2005; 20(Suppl 1): S22.
53. Grisanti M, Niu QT, Fan W, et al. Dkk-1 inhibition increases bone mineral density in rodents. J Bone Miner Res 2006; 21(Suppl 1): S25.
54. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, et al. Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006; 21: 910-20.
55. Hayashibara T, Hiraga T, Yi B, Nomizu M, Kumagai Y, Nishimura R, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004; 19: 455-62.
56. Lazarov M, Shih M, Negron A. AC-100, a fragment of MEPE, promotes fracture healing in a femoral closed fracture model in rats. J Bone Miner Res 2004; 19(Suppl 1): S456.
57. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-97.